Ronald Feld

18.3k total citations · 5 hit papers
247 papers, 12.9k citations indexed

About

Ronald Feld is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Ronald Feld has authored 247 papers receiving a total of 12.9k indexed citations (citations by other indexed papers that have themselves been cited), including 129 papers in Oncology, 102 papers in Pulmonary and Respiratory Medicine and 55 papers in Epidemiology. Recurrent topics in Ronald Feld's work include Lung Cancer Treatments and Mutations (61 papers), Lung Cancer Research Studies (57 papers) and Neutropenia and Cancer Infections (35 papers). Ronald Feld is often cited by papers focused on Lung Cancer Treatments and Mutations (61 papers), Lung Cancer Research Studies (57 papers) and Neutropenia and Cancer Infections (35 papers). Ronald Feld collaborates with scholars based in Canada, United States and France. Ronald Feld's co-authors include Frances A. Shepherd, William K. Evans, Kenneth V. I. Rolston, Natasha B. Leighl, Gerald P. Bodey, Walter T. Hughes, Jerry L. Shenep, Philip A. Pizzo, Lowell S. Young and Arthur E. Brown and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Ronald Feld

244 papers receiving 12.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer

2002 1.4k citations Ronald Feld et al. profile →
The Multinational Association for Supportive Care in Cancer Risk Index: A Multinational Scoring System for Identifying Low-Risk Febrile Neutropenic Cancer Patients

2000 768 citations Ronald Feld et al. Journal of Clinical Oncology profile →
Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.

1988 544 citations Nevin Murray, William K. Evans et al. Journal of Clinical Oncology profile →
1997 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever

1997 503 citations Ronald Feld et al. profile →
Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials

2015 330 citations Massimo Di Maïo, Ciro Gallo et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Ronald Feld	8.0k	4.6k	3.2k	1.8k	1.7k	247	12.9k
Linda S. Elting	7.4k 0.9×	6.4k 1.4×	2.2k 0.7×	1.5k 0.8×	916 0.5×	195	15.6k
Jean Klášterský	7.0k 0.9×	2.4k 0.5×	3.2k 1.0×	3.2k 1.8×	1.2k 0.7×	459	13.1k
Robert Wesley	3.2k 0.4×	3.2k 0.7×	3.0k 0.9×	517 0.3×	1.6k 0.9×	158	13.7k
David C. Dale	8.3k 1.0×	2.1k 0.4×	2.0k 0.6×	947 0.5×	2.1k 1.2×	337	19.6k
Emil Frei	7.3k 0.9×	3.4k 0.7×	1.1k 0.3×	208 0.1×	3.1k 1.8×	272	15.8k
Joseph Aisner	5.2k 0.7×	3.9k 0.9×	2.4k 0.8×	135 0.1×	1.9k 1.1×	308	10.8k
Paolo Bruzzi	5.1k 0.6×	1.7k 0.4×	1.5k 0.5×	260 0.1×	2.0k 1.2×	325	14.3k
James F. Holland	5.6k 0.7×	2.1k 0.4×	1.6k 0.5×	181 0.1×	4.3k 2.5×	400	15.6k
Joseph P. Lynch	1.5k 0.2×	9.2k 2.0×	4.2k 1.3×	314 0.2×	2.0k 1.1×	270	18.6k
Robert L. Danner	903 0.1×	1.2k 0.3×	4.3k 1.3×	676 0.4×	2.3k 1.3×	193	12.2k

Countries citing papers authored by Ronald Feld

Since Specialization

Citations

This map shows the geographic impact of Ronald Feld's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronald Feld with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronald Feld more than expected).

Fields of papers citing papers by Ronald Feld

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronald Feld. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronald Feld. The network helps show where Ronald Feld may publish in the future.

Co-authorship network of co-authors of Ronald Feld

This figure shows the co-authorship network connecting the top 25 collaborators of Ronald Feld. A scholar is included among the top collaborators of Ronald Feld based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronald Feld. Ronald Feld is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sung, Mike, Lisa W. Le, Frances A. Shepherd, et al.. (2017). Evolution of Symptom Burden of Advanced Lung Cancer Over a Decade. Clinical Lung Cancer. 18(3). 274–280.e6. 73 indexed citations

Zer, Alona, Mor Moskovitz, David Hwang, et al.. (2017). OA21.02 ALK-Rearranged Non-Small Cell Lung Cancer is Associated with a High Rate of Venous Thromboembolism. Journal of Thoracic Oncology. 12(1). S326–S327. 1 indexed citations

Sung, Mike, et al.. (2016). Patients with Advanced Non–Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials?. Journal of Thoracic Oncology. 11(1). 79–84. 47 indexed citations

Wheatley‐Price, Paul, Quincy S. Chu, Maria Bonomi, et al.. (2016). A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207. Journal of Thoracic Oncology. 11(11). 2018–2021. 29 indexed citations

Pass, Harvey I., Chandra Goparaju, Osvaldo Espin‐Garcia, et al.. (2016). Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. 11(6). 900–909. 18 indexed citations

Maïo, Massimo Di, Ciro Gallo, Natasha B. Leighl, et al.. (2015). Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials. Journal of Clinical Oncology. 33(8). 910–915. 330 indexed citations breakdown →

Brade, Anthony, Robert M. MacRae, Scott A. Laurie, et al.. (2015). Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable Non–Small Cell Lung Cancer. Clinical Lung Cancer. 17(2). 133–141. 8 indexed citations

Perrot, Marc de, Ronald Feld, Natasha B. Leighl, et al.. (2015). Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma. Journal of Thoracic and Cardiovascular Surgery. 151(2). 468–475. 90 indexed citations

Lim, Chétana, Ming‐Sound Tsao, Lisa W. Le, et al.. (2015). Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer. Annals of Oncology. 26(7). 1415–1421. 179 indexed citations

10.

Laurie, Scott A., Ashish Gupta, Quincy S. Chu, et al.. (2011). Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group. Journal of Thoracic Oncology. 6(11). 1950–1954. 52 indexed citations

11.

Coate, Linda, Christine Massey, Andrew Hope, et al.. (2011). Treatment of the Elderly When Cure is the Goal: The Influence of Age on Treatment Selection and Efficacy for Stage III Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 6(3). 537–544. 44 indexed citations

12.

Laurie, Scott A., Keyue Ding, Ronald Feld, et al.. (2007). The impact of anemia on outcome of chemoradiation for limited small-cell lung cancer: a combined analysis of studies of the National Cancer Institute of Canada Clinical Trials Group. Annals of Oncology. 18(6). 1051–1055. 10 indexed citations

13.

Benamore, Rachel, Frances A. Shepherd, Natasha B. Leighl, et al.. (2007). Does Intensive Follow-up Alter Outcome in Patients with Advanced Lung Cancer?. Journal of Thoracic Oncology. 2(4). 273–281. 38 indexed citations

14.

Pujol, Jean-Louis, et al.. (2006). Gefitinib (IRESSA) with Vinorelbine or Vinorelbine/Cisplatin for Chemotherapy-Naive Non-small Cell Lung Cancer Patients. Journal of Thoracic Oncology. 1(5). 417–424. 19 indexed citations

15.

Visbal, A., Natasha B. Leighl, Ronald Feld, & Frances A. Shepherd. (2005). Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer. CHEST Journal. 128(4). 2933–2943. 57 indexed citations

16.

Shepherd, Frances A., et al.. (1991). Surgical treatment for limited small-cell lung cancer. Journal of Thoracic and Cardiovascular Surgery. 101(3). 385–393. 95 indexed citations

17.

Feld, Ronald. (1989). Late Complications Associated with the Treatment of Small-Cell Lung Cancer. Cancer treatment and research. 45. 301–323. 1 indexed citations

18.

Feld, Ronald, Gerald H. Clamon, Ronald H. Blum, et al.. (1985). Short course prophylactic cranial irradiation for small cell lung cancer. American Journal of Clinical Oncology. 8(5). 371–376. 15 indexed citations

19.

Shike, Moshe, Errol B. Marliss, Allan S. Detsky, et al.. (1984). Effects of total parenteral nutrition and chemotherapy on the metabolic derangements in small cell lung cancer.. PubMed. 44(4). 1706–11. 68 indexed citations

20.

Shepherd, Frances A., Robert J. Ginsberg, William K. Evans, et al.. (1983). Reduction in local recurrence and improved survival in surgically treated patients with small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery. 86(4). 498–506. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact